论文部分内容阅读
目的 应用结直肠癌单克隆抗体对胃肠癌患者进行血清学诊断。 方法 采用ELISA法对胃癌、结直肠癌、胃良性疾病和健康供血者血清中结直肠癌抗原(CCA)进行了测定,同时测定了胃癌、结直肠癌患者血清中CEA含量。 结果 正常人血清CCA阳性仅1.5％。胃癌血清阳性率52.8％,CEA阳性率24.5％,CEA阳性病例中CCA阳性率为30.0％。结直肠癌患者CCA阳性率为52.9％,CEA阳性率为20.6％,CEA阴性病例中CCA阳性率为48.2％。胃良性疾病组CCA阳性率为10％。 结论 CCA单抗与CEA无交叉反应,临床上测定CCA可作为CEA的补充,为临床诊断及普查提供了新的诊断指标。
Objective To apply serological colorectal cancer monoclonal antibodies to serological diagnosis of gastrointestinal cancer. Methods The colorectal cancer antigen (CCA) in serum of gastric cancer, colorectal cancer, benign gastric disease and healthy blood donors was determined by ELISA. CEA levels in serum of patients with gastric cancer and colorectal cancer were measured. Results Serum CCA was only 1.5% positive in normal subjects. The positive rate of seropositivity in gastric cancer was 52.8%, the positive rate of CEA was 24.5%, and the positive rate of CCA in positive cases was 30.0%. In patients with colorectal cancer, the positive rate of CCA was 52.9%, the positive rate of CEA was 20.6%, and the positive rate of CCA in the CEA negative cases was 48.2%. The positive rate of CCA in the benign gastric disease group was 10%. Conclusion There is no cross reaction between CCA monoclonal antibody and CEA. Clinically, CCA determination can be used as a supplement to CEA and provide new diagnostic indicators for clinical diagnosis and census.